Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Existing Safety Dental Needles Not Safer Than Traditional Needles, Study Says

This article was originally published in The Gray Sheet

Executive Summary

Currently available dental needles with safety features designed to prevent accidental needlesticks are not superior to traditional needles in terms of safety, according to a study published in the July edition of the Journal of the California Dental Association.

You may also be interested in...



MedPro Believes Needlyzer Meets Revised Cal/OSHA Standard

Needle destruction devices can qualify as "engineering controls" as specified in California's revised Bloodborne Pathogen Standard, according to the Standards Board of the California Occupational Safety and Health (Cal/OSHA).

MedPro Believes Needlyzer Meets Revised Cal/OSHA Standard

Needle destruction devices can qualify as "engineering controls" as specified in California's revised Bloodborne Pathogen Standard, according to the Standards Board of the California Occupational Safety and Health (Cal/OSHA).

Federal Safe Needle Bill Mandates Use Of Sharps With Protective Features

Legislation introduced in the House May 20 by Reps. Pete Stark (D-Calif.) and Marge Roukema (R-N.J.) would amend the Occupational Safety and Health Administration's bloodborne pathogen standard to require that employers use needleless systems and sharps with engineered safety features to reduce the risk of accidental needlesticks among health care workers.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel